Japan's Mitsubishi Chemical Group has picked U.S. investment fund Bain Capital as the preferred bidder for its pharmaceutical ...

Mitsubishi Chemical Group has given the U.S. investment fund Bain Capital the right of first refusal to negotiate the ...

The U.S. investment company is in the final stages of negotiations to buy the subsidiary, Mitsubishi Tanabe Pharma, for possibly more than 500 billion yen, equivalent to $3.21 billion, the person ...

Investment firm Bain Capital is in talks to acquire Mitsubishi Tanabe Pharma Corp., affiliated to Japan's Mitsubishi Chemical Group ...

TOKYO -- Japan's Mitsubishi Chemical Group has granted a first-refusal right to U.S. investment fund Bain Capital for the purchase of its pharmaceutical subsidiary Mitsubishi Tanabe Pharma, Nikkei has ...

Mitsubishi Chemical Group is stepping up its efforts to streamline operations by entering negotiations with U.S. investment ...

The following are the top stories in the Wall Street Journal. - Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Global private equity firms Blackstone and Bain Capital are among final bidders for Mitsubishi Tanabe Pharma, a unit of Japan's Mitsubishi Chemical Group, in a deal that could value it at between ...

Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at www.lonza.com Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of ...

(RTTNews) - Investment firm Bain Capital is in talks to acquire Mitsubishi Tanabe Pharma Corp., affiliated to Japan's Mitsubishi Chemical Group (MTLHF.PK), in a potential deal, reports said citing ...